The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
Primary Purpose
Diabetes, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
insulin degludec
insulin detemir
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Either - Black or African American not of Hispanic or Latino origin or - White of Hispanic or Latino origin or - White not of Hispanic or Latino origin
- Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months
- Treated with insulin for at least 3 months, alone or in combination with maximum 2 oral antidiabetic drugs (OADs)
- Body mass index maximum 40.0 kg/m^2
Exclusion Criteria:
- Use of GLP-1 receptor agonists (exenatide, liraglutide), thiazolidinediones or dipeptidyl peptidase-4 (DPP-4) inhibitors within 3 months prior to screening
- History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
- Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
Sites / Locations
- Novo Nordisk Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Active Comparator
Active Comparator
Experimental
Arm Label
A1, first period
A2, second period
B1, first period
B2, second period
Arm Description
Outcomes
Primary Outcome Measures
Area under the glucose infusion rate curve during one dosing interval at steady state
Secondary Outcome Measures
Area under the Insulin Degludec concentration-time curve during one dosing interval at steady state
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01043510
Brief Title
The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
Official Title
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of NN1250 at Steady State Conditions in Subjects With Type 2 Diabetes of Different Race and/or Ethnicity
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the pharmacodynamic (effect) and pharmacokinetic (exposure of drug) properties of NN1250 (insulin degludec, IDeg) in subjects with type 2 diabetes of different race and/or ethnicity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
63 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A1, first period
Arm Type
Experimental
Arm Title
A2, second period
Arm Type
Active Comparator
Arm Title
B1, first period
Arm Type
Active Comparator
Arm Title
B2, second period
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
insulin degludec
Intervention Description
0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
Intervention Type
Drug
Intervention Name(s)
insulin detemir
Intervention Description
0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
Primary Outcome Measure Information:
Title
Area under the glucose infusion rate curve during one dosing interval at steady state
Time Frame
0-24 hours (derived on treatment day 6)
Secondary Outcome Measure Information:
Title
Area under the Insulin Degludec concentration-time curve during one dosing interval at steady state
Time Frame
0-24 hours (derived on treatment day 6)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Either - Black or African American not of Hispanic or Latino origin or - White of Hispanic or Latino origin or - White not of Hispanic or Latino origin
Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months
Treated with insulin for at least 3 months, alone or in combination with maximum 2 oral antidiabetic drugs (OADs)
Body mass index maximum 40.0 kg/m^2
Exclusion Criteria:
Use of GLP-1 receptor agonists (exenatide, liraglutide), thiazolidinediones or dipeptidyl peptidase-4 (DPP-4) inhibitors within 3 months prior to screening
History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Chula Vista
State/Province
California
ZIP/Postal Code
91911
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
24508419
Citation
Hompesch M, Morrow L, Watkins E, Roepstorff C, Thomsen HF, Haahr H. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus. Clin Ther. 2014 Apr 1;36(4):507-15. doi: 10.1016/j.clinthera.2013.12.014. Epub 2014 Feb 5.
Results Reference
result
PubMed Identifier
25581159
Citation
Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, Segel S, Kapur R, Haahr H, Hompesch M. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. J Diabetes. 2016 Jan;8(1):132-8. doi: 10.1111/1753-0407.12266. Epub 2015 Mar 24.
Results Reference
result
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
We'll reach out to this number within 24 hrs